Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on November 16, 2023. The company is an emerging growth company incorporated in Delaware. The report addresses critical compliance issues regarding its continued listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing references financial data from the Quarterly Report on Form 10-Q for the period ended September 30, 2023.
- Stockholders' Equity: ($3,379,000) as of September 30, 2023.
- Stock Price: Closed below $1.00 per share for 30 consecutive business days prior to October 27, 2023.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes and Listing Status
The company faces two distinct delisting determinations from Nasdaq:
- Minimum Bid Price Deficiency: On October 27, 2023, Nasdaq notified the company that its stock price fell below the $1.00 minimum requirement (Listing Rule 5550(a)(2)), triggering a delisting determination.
- Stockholders' Equity Deficiency: On November 16, 2023, Nasdaq notified the company that its stockholders' equity of ($3,379,000) failed to meet the $2.5 million minimum requirement (Listing Rule 5550(b)(1)).
Previously, in July 2023, the company had regained compliance with the equity requirement but was placed under a Mandatory Panel Monitor until July 14, 2024. The new equity deficiency renders the company ineligible for a standard 180-day compliance period.
Outlook, Management Commentary, and Risks
The company has appealed the delisting determination regarding the bid price and will present its views on the equity deficiency at a scheduled hearing. A Nasdaq Hearing Panel hearing is set for February 1, 2024. The primary risk is the removal of the company's common stock from The Nasdaq Capital Market if the panel upholds the delisting determinations.
Key Facts for Investor Verification
- Verify the outcome of the Nasdaq Hearing Panel scheduled for February 1, 2024.
- Confirm the company's current stockholders' equity position relative to the $2.5 million threshold.
- Monitor the trading price of ALLR to assess compliance with the $1.00 minimum bid price rule.
- Review the full Form 10-Q for the period ended September 30, 2023, for detailed financial statements not included in this 8-K.